DE69833316D1 - Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen - Google Patents

Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen

Info

Publication number
DE69833316D1
DE69833316D1 DE69833316T DE69833316T DE69833316D1 DE 69833316 D1 DE69833316 D1 DE 69833316D1 DE 69833316 T DE69833316 T DE 69833316T DE 69833316 T DE69833316 T DE 69833316T DE 69833316 D1 DE69833316 D1 DE 69833316D1
Authority
DE
Germany
Prior art keywords
diagnosis
therapy
cancer
ulip
neurologic syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69833316T
Other languages
English (en)
Other versions
DE69833316T2 (de
Inventor
Michpile Aguera
Marie-Franupsilonoise Belin
Jomegarrhome Honnorat
Pappachan Kolattukudy
Tam Quach
Tamara Byk
Andromega Sobel
Dominique Aunis
Jean-Christophe Antoine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE69833316D1 publication Critical patent/DE69833316D1/de
Application granted granted Critical
Publication of DE69833316T2 publication Critical patent/DE69833316T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69833316T 1997-02-19 1998-02-19 Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen Expired - Fee Related DE69833316T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9701961 1997-02-19
FR9701961A FR2759701B1 (fr) 1997-02-19 1997-02-19 Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
PCT/FR1998/000328 WO1998037192A1 (fr) 1997-02-19 1998-02-19 Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques

Publications (2)

Publication Number Publication Date
DE69833316D1 true DE69833316D1 (de) 2006-04-13
DE69833316T2 DE69833316T2 (de) 2006-09-28

Family

ID=9503917

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833316T Expired - Fee Related DE69833316T2 (de) 1997-02-19 1998-02-19 Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen

Country Status (8)

Country Link
US (2) US7183400B1 (de)
EP (1) EP0980427B1 (de)
JP (1) JP2001512971A (de)
AT (1) ATE316574T1 (de)
DE (1) DE69833316T2 (de)
ES (1) ES2257804T3 (de)
FR (1) FR2759701B1 (de)
WO (1) WO1998037192A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60121735T4 (de) * 2000-02-29 2010-07-08 Institut National De La Santé Et De La Recherche Médicale (Inserm) Neues menschliches ULIP/CRMP-Protein und seine Verwendung bei der Diagnose und Behandlung von Krebsen und paraneoplastischen neurologischen Syndromen
FR2805540B1 (fr) * 2000-02-29 2004-04-09 Inst Nat Sante Rech Med Nouvelle proteine ulip humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
FR2807757B1 (fr) * 2000-04-18 2004-08-13 Inst Nat Sante Rech Med Nouvelle proteine ulip/crmp humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques et paraneoplastiques
WO2002002620A2 (en) * 2000-06-29 2002-01-10 Mayo Foundation For Medical Education And Research Crmp-5 (collapsin response-mediator protein) encoding nucleic acid, polypeptide and uses thereof
ZA200204907B (en) * 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
FR2829392B1 (fr) * 2001-09-07 2005-09-16 Inst Nat Sante Rech Med Utilisation de crmps pour la fabrication d'un medicament destine a traiter les maladies liees a un dysfonctionnement du systeme immunitaire
WO2003022298A2 (fr) 2001-09-07 2003-03-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire
FR2830762B1 (fr) * 2001-10-16 2004-10-22 Inst Nat Sante Rech Med Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire
US20120196307A1 (en) * 2007-02-06 2012-08-02 Banyan Biomarkers, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
JP2012533079A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 中枢神経系の炎症疾病の血液マーカーとしての切断およびリン酸化されたｃｒｍｐ２
WO2016154559A1 (en) * 2015-03-25 2016-09-29 Indiana University Research And Technology Corporation Peptides that modulate the effect of the crmp: neurofibromin complex on synaptic transmission
EP3564670A1 (de) * 2018-05-03 2019-11-06 Hospices Civils de Lyon Antikörper gegen trim9 und/oder trim67 in paraneoplastischen neurologischen syndromen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL108587A (en) * 1993-02-09 1998-01-04 Univ Monash Methods and kit for diagnosing diabetes and pre-diabetic conditions
US5723343A (en) * 1995-08-28 1998-03-03 University Of Florida Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor

Also Published As

Publication number Publication date
ATE316574T1 (de) 2006-02-15
JP2001512971A (ja) 2001-08-28
WO1998037192A1 (fr) 1998-08-27
FR2759701B1 (fr) 1999-06-04
US7183400B1 (en) 2007-02-27
EP0980427B1 (de) 2006-01-25
EP0980427A1 (de) 2000-02-23
FR2759701A1 (fr) 1998-08-21
DE69833316T2 (de) 2006-09-28
US20070117166A1 (en) 2007-05-24
ES2257804T3 (es) 2006-08-01

Similar Documents

Publication Publication Date Title
ATE302414T1 (de) Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
DE69833316D1 (de) Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
ID28623A (id) Turunan 2-amino-tiazol, proses pembuatannya, dan penggunaannya sebagai zat anti tumor
ID28971A (id) Turunan 2-ureido-tiazol, proses pembuatannya, dan penggunaannya sebagai zat anti tumor
DE60136099D1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
BR9707125A (pt) Composições e processos para o tratamento e diagnóstico de câncer de mama
TR199501441A2 (tr) Islevsel poliorganosiloksanlar ve bunlarin hazirlanmasina mahsus islemlerden bir tanesi.
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE163195T1 (de) Lösliche liganden für cd40
TR200200937T2 (tr) Yumurtalık kanseri tedavisi için bileşimler.
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
ATE378356T1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
NL190399B (nl) Ijzer-bevattend eiwitmateriaal, bereiding daarvan, en farmaceutisch preparaat voor de behandeling van sideropene anaemie.
DE69534325D1 (de) Peptide zur behandlung von krebs
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee